SOHO 2021 | MANHATTAN: carfilzomib, lenalidomide, dexamethasone, and daratumumab for newly diagnosed myeloma
Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, outlines the findings of the MANHATTAN trial, a Phase II, nonrandomized trial investigating the safety and efficacy of carfilzomib, lenalidomide, dexamethasone, and daratumumab in combination for patients with newly diagnosed multiple myeloma. Dr Landgren reports that 71% of patients, none of whom had received a prior bone marrow transplantation, achieved measurable residual disease (MRD) negativity. All drugs were shown to be well tolerated. Dr Landgren goes on to compare these findings to those of the GRIFFIN trial (NCT02874742), which is investigating daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVd) to lenalidomide, bortezomib and dexamethasone (RVd) in patients with newly diagnosed multiple myeloma. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
